These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15914281)

  • 1. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
    Ito T; Ouchida M; Morimoto Y; Yoshida A; Jitsumori Y; Ozaki T; Sonobe H; Inoue H; Shimizu K
    Cancer Lett; 2005 Jun; 224(2):311-9. PubMed ID: 15914281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
    Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
    Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
    Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H
    Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
    Kobayashi Y; Ohtsuki M; Murakami T; Kobayashi T; Sutheesophon K; Kitayama H; Kano Y; Kusano E; Nakagawa H; Furukawa Y
    Oncogene; 2006 Jan; 25(4):512-24. PubMed ID: 16186804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
    Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
    Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
    Savickiene J; Treigyte G; Borutinskaite V; Navakauskiene R; Magnusson KE
    Ann N Y Acad Sci; 2006 Dec; 1091():368-84. PubMed ID: 17341629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.
    Sawa H; Murakami H; Kumagai M; Nakasato M; Yamauchi S; Matsuyama N; Tamura Y; Satone A; Ide W; Hashimoto I; Kamada H
    Acta Neuropathol; 2004 Jun; 107(6):523-31. PubMed ID: 15024582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
    Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT
    J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibitory effect of a novel histone deacetylases inhibitor FK228 on human colon cancer HCT-116 cells in vitro and in vivo].
    Xu DB; Wang YL; Yue Y; Wu SC; Ding H
    Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):814-8. PubMed ID: 24447477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
    Hoshino I; Matsubara H; Akutsu Y; Nishimori T; Yoneyama Y; Murakami K; Komatsu A; Sakata H; Matsushita K; Ochiai T
    Oncol Rep; 2007 Sep; 18(3):585-92. PubMed ID: 17671705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
    Matsubara H; Watanabe M; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Kamitsuji Y; Watanabe K; Nishijo K; Toguchida J; Nakahata T; Adachi S
    J Pharmacol Exp Ther; 2009 Mar; 328(3):839-48. PubMed ID: 19073909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.
    Sasakawa Y; Naoe Y; Sogo N; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
    Biochem Pharmacol; 2005 Feb; 69(4):603-16. PubMed ID: 15670579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depsipeptide (FK228) inhibits growth of human prostate cancer cells.
    Lai MT; Yang CC; Lin TY; Tsai FJ; Chen WC
    Urol Oncol; 2008; 26(2):182-9. PubMed ID: 18312939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin.
    Cao H; Stamatoyannopoulos G
    Am J Hematol; 2006 Dec; 81(12):981-3. PubMed ID: 16888791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
    Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
    Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
    Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
    Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
    J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis.
    Yamamura K; Ohishi K; Katayama N; Yu Z; Kato K; Masuya M; Fujieda A; Sugimoto Y; Miyata E; Shibasaki T; Heike Y; Takaue Y; Shiku H
    Br J Haematol; 2006 Oct; 135(2):242-53. PubMed ID: 16939493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
    Sasakawa Y; Naoe Y; Noto T; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
    Biochem Pharmacol; 2003 Sep; 66(6):897-906. PubMed ID: 12963476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.